Quince Therapeutics, Inc.

Quince Therapeutics, Inc.

IRLA - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$478.75M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Quince Therapeutics, Inc.Quince Therapeutics, Inc.-1.9-163%--
$70.00

Target Price by Analysts

75.5% upsideQuince Therapeutics Target Price DetailsTarget Price

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$478.75 Million
Enterprise Value$438.93 Million
Earnings per Share$-336
Beta1.33
Outstanding Shares12,004,791

Return

Return on Equity162.51%ROE
Return on Assets-100.29%
Return on Invested Capital-127.76%

Valuation & Multiples

P/E Ratio-1.88P/E Ratio
PEG-1.76PEG
Price to Sales-Price to Sales
Price to Book Ratio6.65Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-3.46
Enterprise Value to Net Income-5
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$2.31
Est. -$1.38
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
March 23, 2027
EPS Estimate
-$1.54
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Cortexyme Inc

38 employees
CEO: Dirk Thye

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Pha...

Questions & Answers